Technology Innovation Institute (TII) and Burjeel Medical City (BMC) are partnering to develop novel immunotherapy solutions for cancer treatment, focusing on T-cell based therapeutics like CAR-T and TIL therapy. In the first phase, TII will construct a computational platform to identify patient-specific antigens from single-cell transcriptomics data, enabling the design of CAR-T cells. The two-year partnership aims to boost the body's immune system to fight cancer and personalize cancer therapies using TII's technologies. Why it matters: This collaboration signifies the UAE's commitment to advancing cancer care through collaborative research and innovative solutions, potentially establishing the country as a leader in personalized oncology treatments.
The Russian Immune Diversity Atlas project aims to profile immune cells from people of different ancestries at a multiomics level. The goal is to reconstruct a reference atlas of the healthy immune system and investigate its perturbations in Type II Diabetes (T2D). The project seeks to identify novel mechanisms and genetic/epigenetic markers for early T2D diagnostics, prognosis, and therapy as part of the international Human Cell Atlas. Why it matters: Addressing genetic diversity in biomedical research, particularly in the context of the Human Cell Atlas, is crucial for personalized medicine and ensuring that treatments are effective across diverse populations in the Middle East and globally.
Petar Stojanov from the Broad Institute of MIT and Harvard will give a talk on cancer data analysis, covering the fundamentals of cancer, the nature of large-scale data collected, and main analysis objectives. The talk will also address open questions in cancer data analysis and how machine learning and generative modeling can help. Stojanov's research focuses on applying machine learning to genomic analysis of cancer mutation and single-cell RNA sequencing data. Why it matters: Applying AI and machine learning to cancer research can lead to a better understanding of the disease and development of new therapies.
A talk discusses the challenges of single-cell data analysis, such as feature sparsity and the effects of rare cells. AI/ML strategies are uniquely positioned to model this data. ImYoo, a startup founded in 2021, is applying single-cell model architectures for unsupervised discovery of patient groupings and predicting sample-level phenotypical data in autoimmune disease. Why it matters: This highlights the growing application of AI/ML in analyzing single-cell data for population-scale human health studies, an area ripe for innovation and improvement in the Middle East's growing biotech sector.
A senior lecturer at the University of New South Wales discussed the use of AI to improve early prognosis and personalized treatment plans for neurodegenerative diseases, cardiovascular imaging and multiomics. The lecture highlighted the potential of AI algorithms to detect subtle changes at early stages through advanced multiomics techniques and medical imaging analysis. The speaker has expertise in analyzing medical images and has collaborated with medical professionals to develop AI tools for diagnosis of cancer, neurodegenerative disease, and heart disease. Why it matters: AI-driven prognosis and treatment planning promises earlier intervention and improved outcomes for challenging diseases in the region.
Eduardo da Veiga Beltrame, bioinformatics lead at ImYoo (a Caltech spinout), presented on scalable methods for single-cell omics data analysis, including kallisto|bustools and scvi-tools. He highlighted their use in ImYoo's decentralized longitudinal study on Inflammatory Bowel Disease (IBD), where patients self-collect capillary blood samples. Beltrame also discussed his research on STEM education programs in Brazil as a visiting scholar at UC Berkeley. Why it matters: This highlights the growing trend of decentralized clinical studies leveraging advanced single-cell technologies for precision medicine, showcasing the potential of remote data collection and analysis in understanding complex diseases.
KAUST researchers developed a statistical approach to improve the identification of cancer-related protein mutations by reducing false positives. The method uses Bayesian statistics to analyze protein domain data from tumor samples, accounting for potential errors due to limited data. The team tested their method on prostate cancer data, successfully identifying a known cancer-linked mutation in the DNA binding protein cd00083. Why it matters: This enhances the reliability of cancer research at the molecular level, potentially accelerating the discovery of new therapeutic targets.
This article discusses the use of artificial intelligence in precision oncology, particularly in understanding individual tumor mechanisms and aiding clinical decision-making. Dr. Xinghua Lu, with extensive experience in medicine and biomedical informatics, will present research on individualized Bayesian causal inference methods for investigating oncogenic mechanisms. These methods aim to provide clinical decision support at the cellular, tumor, and patient levels. Why it matters: AI-driven precision oncology can enable more personalized and effective cancer treatments, improving patient outcomes in the region and globally.